In this cohort study of 318 patients treated with adjuvant anti–PD-1 therapy for advanced and metastatic melanoma, 63.3% of patients with chronic irAEs (29.2% of all patients with adjuvant PD-1 therapy) experienced persistent irAEs with prolonged follow up. The gene discussed is PDCD1; the disease is metastatic melanoma.